Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1794-1801

  Chute, John P ^a   Chen, Timothy ^a   Feigal, Ellen ^a   Simon, Richard ^a   Johnson, Bruce E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; PROCARBAZINE; VINCRISTINE;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0032998171     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1794     Document Type: Article

References (37)

1. Ihde DC: Chemotherapy of lung cancer. N Engl J Med 327:1434-1441, 1992
2. Albain KS, Crowley JJ, LeBlanc M, et al: Determinants of improved outcome in small-cell lung cancer: An analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 8:1563-1574, 1990
3. Spiegelman D, Maurer LH, Ware JH, et al: Prognostic factors in small-cell carcinoma of the lung: An analysis of 1,521 patients. J Clin Oncol 7:344-354, 1989
4. Ihde DC, Glatstein EJ, Pass HI: Small-cell lung cancer, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 911-950
5. Chute JP, Venzon D, Hankins L, et al: Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clin Proc 72:901-912, 1997
6. Aisner J: Extensive-disease small-cell lung cancer: The thrill of victory; the agony of defeat. J Clin Oncol 14:658-665, 1996
7. The SEER 1973-1994 Public Use Data, SEER*Stat [computer database]. Version 1.0 for Windows 95/NT. Bethesda, MD, National Cancer Institute, 1997
8. Snedecor GW, Cochran WG: Statistical Methods (ed 6). Ames, IA, Iowa State University Press, 1967
9. Maurer LH, Tulloh M, Weiss RB, et al: A randomized combined modality trial in small cell carcinoma of the lung: Comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiation. Cancer 45:30-39, 1980
10. Ettinger DS, Lagakos S: Phase III study of CCNU, cyclophosphamide, adriamycin, vincristine, and VP-16 in small-cell carcinoma of the lung. Cancer 49:1544-1554, 1982
11. Lowenbraun S, Bartolucci A, Smalley RV, et al: The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer 44:406-413, 1979
12. McCracken JD, Heilbrun L, White J, et al: Combination chemotherapy, radiotherapy, and BCG immunotherapy in extensive (metastatic) small cell carcinoma of the lung: A Southwest Oncology Group study. Cancer 46:2335-2340, 1980
13. Daniels JR, Chak LY, Sikic BI, et al: Chemotherapy of small-cell carcinoma of lung: A randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol 2:1192-1199, 1984
14. Livingston RB, Mira JG, Chen TT, et al: Combined modality treatment of extensive small cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 2:585-590, 1984
15. Sandler A, Jirotek M, Vogl S, et al: A comparison of standard with intensive combination chemotherapy in small-cell lung cancer, mature results: An Eastern Cooperative Oncology Group Trial (ECOG). Proc Am Soc Clin Oncol 16:418a, 1997 (abstr 1730)
16. Jackson DV Jr, Case LD, Zekan PJ, et al: Improvement of long-term survival in extensive small-cell lung cancer. J Clin Oncol 6:1161-1169, 1988
17. Everson LK, Jett JR, O'Fallon JR, et al: Alternating chemotherapy with or without VP-16 in extensive-stage small-cell lung cancer. Am J Clin Oncol 12:339-344, 1989
18. Hong WK, Nicaise C, Lawson R, et al: Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: A randomized trial of the Bristol Lung Cancer Study Group. J Clin Oncol 7:450-456, 1989
19. Chahinian AP, Propert KJ, Ware JH, et al: A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 7:993-1002, 1989
20. Johnson DH, Einhorn LH, Birch R, et al: A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 5:1731-1738, 1987
21. Evans WK, Feld R, Murray N, et al: Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: A multicenter, randomized clinical trial by the National Cancer Institute of Canada [published erratum appears in Ann Intern Med 108:496, 1988]. Ann Intern Med 107:451-458, 1987
22. Ettinger DS, Finkelstein DM, Abeloff MD, et al: A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: A phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 8:230-240, 1990
23. Livingston RB, Schulman S, Mira JG, et al: Combined alkylators and multiple-site irradiation for extensive small cell lung cancer: A Southwest Oncology Group study. Cancer Treat Rep 70:1395-1401, 1986
24. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992
25. Ettinger DS, Finkelstein DM, Abeloff MD, et al: Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: An Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst 84:1077-1084, 1992
26. Maksymiuk AW, Jett JR, Earle JD, et al: Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: Results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol 12:70-76, 1994
27. Loehrer PJ Sr, Ansari R, Gonin R, et al: Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: A Hoosier Oncology Group study. J Clin Oncol 13:2594-2599, 1995
28. Rowland KM Jr, Loprinzi CL, Shaw EG, et al: Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: A North Central Cancer Treatment Group study. J Clin Oncol 14:135-141, 1996
29. Miller AA, Herndon JE II, Hollis DR, et al: Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: A randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 13:1871-1879, 1995
30. Non-Small-Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:889-909, 1995
31. Fukuoka M, Furuse K, Saijo N, et al: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861, 1991
32. Earl HM, Rudd RM, Spiro SG, et al: A randomised trial of planned versus as required chemotherapy in small cell lung cancer: A Cancer Research Campaign trial. Br J Cancer 64:566-572, 1991
33. Gower NH, Rudd RM, Ruiz de Elvira MC, et al: Assessment of 'quality of life' using a daily diary card in a randomised trial of chemotherapy in small-cell lung cancer. Ann Oncol 6:575-580, 1995
34. Bunn PA Jr, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 4:1087-1100, 1998
35. Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon: Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 12:1604-1608, 1985
36. Chen TT: Statistical aspects of cancer clinical trials, in Buncher CR, Tsay J-Y (eds): Statistics in the Pharmaceutical Industry (ed 2). New York, NY, Marcel Dekker, 1994, pp 143-163
37. Chute JP, Chen T, Feigal E, et al: The use of a statistical model to help predict the outcome of phase III trials of patients (PTS) with extensive stage small cell lung cancer (ES-SCLC). Lung Cancer 18:7, 1997 (suppl 1, abstr)